Trial Profile

An Exploratory Phase II Study to Demonstrate the Safety and Efficacy of A4250 in Children With Cholestatic Pruritus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Odevixibat (Primary)
Indications Alagille syndrome; Biliary atresia; Intrahepatic cholestasis; Primary sclerosing cholangitis; Pruritus
Focus Adverse reactions; Therapeutic Use
Sponsors Albireo AB

Most Recent Events

07 Jun 2019 According to an Albireo Pharma media release, clinical data from this study were presented at the 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting in Glasgow, Scotland.
07 Jun 2019 Results published in the Albireo Pharma Media Release.
23 May 2019 According to an Albireo Pharma media release, data from the study will be presented at the 52nd European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com